Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions

Acinetobacter

  • Pharmacokinetic and Pharmacodynamic Profiling of Minocycline for Injection following a Single Infusion in Critically Ill Adults in a Phase IV Open-Label Multicenter Study (ACUMIN)
    Clinical Therapeutics
    Pharmacokinetic and Pharmacodynamic Profiling of Minocycline for Injection following a Single Infusion in Critically Ill Adults in a Phase IV Open-Label Multicenter Study (ACUMIN)

    Intravenous (i.v.) minocycline is increasingly used to treat infections caused by multidrug-resistant (MDR) Acinetobacter baumannii. Despite its being approved nearly 50 years ago, published information on its pharmacokinetic (PK) profile is limited. This multicenter study examined the PK and probability of pharmacokinetic-pharmacodynamic (PK-PD) target attainment...

    Thomas P. Lodise, Scott Van Wart, Zoe M. Sund, Adam M. Bressler, Akram Khan, Amy T. Makley, Yasir Hamad, Robert A. Salata, Fernanda P. Silveira, Matthew D. Sims, Badih A. Kabchi, Mohamed A. Saad, Carrie Brown, Randolph E. Oler, Vance Fowler, Richard G. Wunderink
  • Open Access
    Structural Insights into Inhibition of the <span class="named-content genus-species" id="named-content-1">Acinetobacter</span>-Derived Cephalosporinase ADC-7 by Ceftazidime and Its Boronic Acid Transition State Analog
    Mechanisms of Resistance
    Structural Insights into Inhibition of the Acinetobacter-Derived Cephalosporinase ADC-7 by Ceftazidime and Its Boronic Acid Transition State Analog

    Extended-spectrum class C β-lactamases have evolved to rapidly inactivate expanded-spectrum cephalosporins, a class of antibiotics designed to be resistant to hydrolysis by β-lactamase enzymes. To better understand the mechanism by which Acinetobacter-derived cephalosporinase-...

    Brandy N. Curtis, Kali A. Smolen, Sara J. Barlow, Emilia Caselli, Fabio Prati, Magdalena A. Taracila, Robert A. Bonomo, Bradley J. Wallar, Rachel A. Powers
  • Cefiderocol Resistance in <span class="named-content genus-species" id="named-content-1">Acinetobacter baumannii</span>: Roles of β-Lactamases, Siderophore Receptors, and Penicillin Binding Protein 3
    Mechanisms of Resistance
    Cefiderocol Resistance in Acinetobacter baumannii: Roles of β-Lactamases, Siderophore Receptors, and Penicillin Binding Protein 3

    Cefiderocol is a siderophore cephalosporin active against many multidrug-resistant (MDR) Gram-negative pathogens. We examined the resistance mechanisms in 12 Acinetobacter baumannii strains with cefiderocol MICs ranging from ≤0.03 to >32 μg/ml. Cefiderocol resistance could not be explained by β-lactamase activity. Cefiderocol resistance was associated with reduced...

    Saquib Malik, Monica Kaminski, David Landman, John Quale
  • Comparison of Cefepime-Cefpirome and Carbapenem Therapy for <span class="named-content genus-species" id="named-content-1">Acinetobacter</span> Bloodstream Infection in a Multicenter Study
    Clinical Therapeutics
    Comparison of Cefepime-Cefpirome and Carbapenem Therapy for Acinetobacter Bloodstream Infection in a Multicenter Study

    Carbapenems are currently the preferred agents for the treatment of serious Acinetobacter infections. However, whether cefepime-cefpirome can be used to treat an Acinetobacter bloodstream infection (BSI) if it is active against the causative pathogen(s) is not clear. This study aimed to compare the...

    Yea-Yuan Chang, Ya-Sung Yang, Shang-Liang Wu, Yung-Chih Wang, Te-Li Chen, Yi-Tzu Lee
    and on behalf of the ACTION Study Group
  • <em>In Vitro</em> Activity of KBP-7072, a Novel Third-Generation Tetracycline, against 531 Recent Geographically Diverse and Molecularly Characterized <span class="named-content genus-species" id="named-content-1">Acinetobacter baumannii</span> Species Complex Isolates
    Susceptibility
    In Vitro Activity of KBP-7072, a Novel Third-Generation Tetracycline, against 531 Recent Geographically Diverse and Molecularly Characterized Acinetobacter baumannii Species Complex Isolates

    KBP-7072 is a novel third-generation tetracycline (aminomethylcycline) antibacterial that overcomes common efflux and ribosomal protection resistance mechanisms that cause resistance in older-generation tetracyclines. KBP-7072 completed phase 1 clinical development studies for safety, tolerability, and pharmacokinetics (ClinicalTrials.gov identifier NCT02454361) and multiple ascending doses in healthy subjects (ClinicalTrials.gov...

    Michael D. Huband, Rodrigo E. Mendes, Michael A. Pfaller, Jill M. Lindley, Gregory J. Strand, Vincent J. Benn, Jay Zhang, Li Li, Min Zhang, Xiaojuan Tan, Qingmei Liu, Robert K. Flamm
  • Distinct Mechanisms of Dissemination of NDM-1 Metallo-β-Lactamase in <em>Acinetobacter</em> Species in Argentina
    Epidemiology and Surveillance
    Distinct Mechanisms of Dissemination of NDM-1 Metallo-β-Lactamase in Acinetobacter Species in Argentina

    A 4-year surveillance of carbapenem-resistant Acinetobacter spp. isolates in Argentina identified 40 strains carrying blaNDM-1. Genome sequencing revealed that most were Acinetobacter baumannii, whereas seven represented other Acinetobacter spp. The A. baumannii...

    Mark D. Adams, Fernando Pasteran, German M. Traglia, Jasmine Martinez, Fanny Huang, Christine Liu, Jennifer S. Fernandez, Carolina Lopez, Lisandro J. Gonzalez, Ezequiel Albornoz, Alejandra Corso, Alejandro J. Vila, Robert A. Bonomo, Maria Soledad Ramirez
  • Whole-Genome Characterization of a <span class="named-content genus-species" id="named-content-1">Shewanella algae</span> Strain Coharboring <em>bla</em><sub>CTX-M-15</sub> and <em>armA</em> Genes on a Novel IncC Plasmid
    Letter to the Editor
    Whole-Genome Characterization of a Shewanella algae Strain Coharboring blaCTX-M-15 and armA Genes on a Novel IncC Plasmid
    Andrea Endimiani, Odette J. Bernasconi, Thomas Büdel, Edgar I. Campos-Madueno, Esther Kuenzli, Christoph Hatz, Alessandra Carattoli
  • <em>In Vitro</em> Activity of Sulbactam-Durlobactam against <span class="named-content genus-species" id="named-content-1">Acinetobacter baumannii</span>-<em>calcoaceticus</em> Complex Isolates Collected Globally in 2016 and 2017
    Epidemiology and Surveillance
    In Vitro Activity of Sulbactam-Durlobactam against Acinetobacter baumannii-calcoaceticus Complex Isolates Collected Globally in 2016 and 2017

    Acinetobacter baumannii-calcoaceticus complex (ABC) organisms cause severe infections that are difficult to treat due to preexisting antibiotic resistance. Sulbactam-durlobactam (formerly sulbactam-ETX2514) (SUL-DUR) is a β-lactam–β-lactamase inhibitor combination antibiotic designed to treat serious infections caused by ABC organisms, including multidrug-...

    Sarah M. McLeod, Samir H. Moussa, Meredith A. Hackel, Alita A. Miller
  • Open Access
    <em>In Vitro</em> Activity of Eravacycline against Gram-Negative Bacilli Isolated in Clinical Laboratories Worldwide from 2013 to 2017
    Epidemiology and Surveillance
    In Vitro Activity of Eravacycline against Gram-Negative Bacilli Isolated in Clinical Laboratories Worldwide from 2013 to 2017

    Eravacycline is a novel, fully synthetic fluorocycline antibiotic developed for the treatment of serious infections, including those caused by multidrug-resistant (MDR) pathogens. Here, we evaluated the in vitro activities of eravacycline and comparator antimicrobial agents against a global collection of frequently encountered clinical isolates of Gram-negative bacilli. The CLSI broth microdilution method was used to determine...

    Ian Morrissey, Melanie Olesky, Stephen Hawser, Sibylle H. Lob, James A. Karlowsky, G. Ralph Corey, Matteo Bassetti, Corey Fyfe
  • <em>In Vitro</em> Activity of Minocycline against U.S. Isolates of <span class="named-content genus-species" id="named-content-1">Acinetobacter baumannii-</span><span class="named-content genus-species" id="named-content-2">Acinetobacter calcoaceticus</span> Species Complex, <span class="named-content genus-species" id="named-content-3">Stenotrophomonas maltophilia</span>, and <span class="named-content genus-species" id="named-content-4">Burkholderia cepacia</span> Complex: Results from the SENTRY Antimicrobial Surveillance Program, 2014 to 2018
    Epidemiology and Surveillance
    In Vitro Activity of Minocycline against U.S. Isolates of Acinetobacter baumannii-Acinetobacter calcoaceticus Species Complex, Stenotrophomonas maltophilia, and Burkholderia cepacia Complex: Results from the SENTRY Antimicrobial Surveillance Program, 2014 to 2018

    We evaluated the activity of minocycline and comparator agents against a large number of Stenotrophomonas maltophilia (n = 1,289), Acinetobacter baumannii-Acinetobacter calcoaceticus species complex (n = 1,081),...

    Robert K. Flamm, Dee Shortridge, Mariana Castanheira, Helio S. Sader, Michael A. Pfaller

Pages

  • Next
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
Back to top

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596